Allarity Therapeutics Email Format
Pharmaceutical ManufacturingFlorida, United States11-50 Employees
Allarity Therapeutics is a clinical-stage company focused on precision oncology. It advances a pipeline of in-licensed cancer therapies and uses its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company is publicly traded on NASDAQ (ALLR) and maintains corporate headquarters in Boston, with an R&D facility in Hoersholm, Denmark, and a location in Tarpon Springs, Florida. Its target market comprises clinicians and researchers seeking more personalized cancer care for patients with difficult-to-treat cancers, supported by DRP-guided decisions. In 2026, Allarity reported progress on stenoparib, a dual PARP and WNT pathway inhibitor, advanced in Phase 2 trials with a DRP companion diagnostic.